225 related articles for article (PubMed ID: 38192642)
1. Metformin: update on mechanisms of action on liver diseases.
Ruan G; Wu F; Shi D; Sun H; Wang F; Xu C
Front Nutr; 2023; 10():1327814. PubMed ID: 38192642
[TBL] [Abstract][Full Text] [Related]
2. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
Nguyen G; Park SY; Le CT; Park WS; Choi DH; Cho EH
Biochem Biophys Res Commun; 2018 Jan; 495(4):2649-2656. PubMed ID: 29278707
[TBL] [Abstract][Full Text] [Related]
3. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
[No Abstract] [Full Text] [Related]
4.
Nian F; Wu L; Xia Q; Tian P; Ding C; Lu X
J Clin Transl Hepatol; 2023 Aug; 11(4):763-776. PubMed ID: 37408808
[TBL] [Abstract][Full Text] [Related]
5. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of metformin against palmitate-induced hepatic cell death.
Geng Y; Hernández Villanueva A; Oun A; Buist-Homan M; Blokzijl H; Faber KN; Dolga A; Moshage H
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165621. PubMed ID: 31786336
[TBL] [Abstract][Full Text] [Related]
7. Low-dose metformin targets the lysosomal AMPK pathway through PEN2.
Ma T; Tian X; Zhang B; Li M; Wang Y; Yang C; Wu J; Wei X; Qu Q; Yu Y; Long S; Feng JW; Li C; Zhang C; Xie C; Wu Y; Xu Z; Chen J; Yu Y; Huang X; He Y; Yao L; Zhang L; Zhu M; Wang W; Wang ZC; Zhang M; Bao Y; Jia W; Lin SY; Ye Z; Piao HL; Deng X; Zhang CS; Lin SC
Nature; 2022 Mar; 603(7899):159-165. PubMed ID: 35197629
[TBL] [Abstract][Full Text] [Related]
8. Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway.
Xie F; Zhong Y; Wang D; So KF; Xiao J; Lv Y
Mol Biol Rep; 2022 Aug; 49(8):7837-7848. PubMed ID: 35733070
[TBL] [Abstract][Full Text] [Related]
9. Metformin Inefficiency to Lower Lipids in Vitamin B12 Deficient HepG2 Cells Is Alleviated via Adiponectin-AMPK Axis.
Boachie J; Zammit V; Saravanan P; Adaikalakoteswari A
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140305
[No Abstract] [Full Text] [Related]
10. Exercise and Metformin Intervention Prevents Lipotoxicity-Induced Hepatocyte Apoptosis by Alleviating Oxidative and ER Stress and Activating the AMPK/Nrf2/HO-1 Signaling Pathway in db/db Mice.
Zhang Y; Liu Y; Liu X; Yuan X; Xiang M; Liu J; Zhang L; Zhu S; Lu J; Tang Q; Cheng S
Oxid Med Cell Longev; 2022; 2022():2297268. PubMed ID: 36120597
[TBL] [Abstract][Full Text] [Related]
11. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
12. Metformin regulates palmitate-induced apoptosis and ER stress response in HepG2 liver cells.
Kim DS; Jeong SK; Kim HR; Kim DS; Chae SW; Chae HJ
Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):251-7. PubMed ID: 20038265
[TBL] [Abstract][Full Text] [Related]
13. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
[TBL] [Abstract][Full Text] [Related]
14. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.
Lin MJ; Dai W; Scott MJ; Li R; Zhang YQ; Yang Y; Chen LZ; Huang XS
Oncotarget; 2017 Dec; 8(65):108802-108809. PubMed ID: 29312569
[TBL] [Abstract][Full Text] [Related]
15. Advance of Metformin in Liver Disease.
Bao J; Zhao Y; Xu X; Ling S
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38299294
[TBL] [Abstract][Full Text] [Related]
16. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways.
Yasmin T; Rahman MM; Khan F; Kabir F; Nahar K; Lasker S; Islam MD; Hossain MM; Hasan R; Rana S; Alam MA
Biochem Biophys Rep; 2021 Dec; 28():101168. PubMed ID: 34825068
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PEN2-ATP6AP1 axis as an antiparasitic target for metformin based on phylogeny analysis and molecular docking.
Liu C; Zhang S; Xue J; Zhang H; Yin J
Mol Biochem Parasitol; 2023 Sep; 255():111580. PubMed ID: 37473813
[TBL] [Abstract][Full Text] [Related]
18. Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis.
Su Y; Hou C; Wang M; Ren K; Zhou D; Liu X; Zhao S; Liu X
Int J Biochem Cell Biol; 2023 Apr; 157():106375. PubMed ID: 36716817
[TBL] [Abstract][Full Text] [Related]
19. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
20. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
Gehrke N; Wörns MA; Huber Y; Hess M; Straub BK; Hövelmeyer N; Waisman A; Kim YO; Schuppan D; Galle PR; Schattenberg JM
J Hepatol; 2016 Dec; 65(6):1188-1197. PubMed ID: 27405060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
